37,38 In one prospective, multicenter study of patients with biopsy-proven CLE unresponsive to at least three systemic therapies, including belimumab, all patients achieved a 50% reduction in CLASI-A (CLASI-A-50) at Week 16, highlighting the potential utility of anifrolumab even in highly treatment-resistant disease
[DOI] [Google Scholar] 425.Alven S, Aderibigbe BA
The direct administration of microbiota-derived metabolites, such as short-chain fatty acids (SCFAs) and indole derivatives, has been shown in experimental models to improve insulin sensitivity, reduce inflammation, and promote gut hormone secretion, potentially bypassing the need for sustained microbial engraftment (112)
Dosing deviations were defined as missing injections or if the last two injections prior to blood sampling were administered less than 120 h apart
Cyanocobalamin injection
50mg Glycine